S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:RGEN

Repligen - RGEN Stock Forecast, Price & News

$180.17
-14.98 (-7.68%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$176.96
$190.76
50-Day Range
$154.26
$195.15
52-Week Range
$137.21
$262.26
Volume
784,447 shs
Average Volume
572,897 shs
Market Capitalization
$10.00 billion
P/E Ratio
62.13
Dividend Yield
N/A
Price Target
$224.14

Repligen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
24.4% Upside
$224.14 Price Target
Short Interest
Bearish
7.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.30
Upright™ Environmental Score
News Sentiment
0.31mentions of Repligen in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$5 M Sold Last Quarter
Proj. Earnings Growth
-7.26%
From $3.17 to $2.94 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

679th out of 1,049 stocks

Biological Products, Except Diagnostic Industry

104th out of 170 stocks


RGEN stock logo

About Repligen (NASDAQ:RGEN) Stock

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

Repligen (NASDAQ:RGEN) Sees Unusually-High Trading Volume
Analyzing Repligen (NASDAQ:RGEN) and ProKidney (NASDAQ:PROK)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Why Shares of Repligen Rose This Week
HZNP vs. RGEN: Which Stock Is the Better Value Option?
Become an Investor in Brooklyn Gin
Award winning super-premium craft gin and upcoming Brooklyn distillerypixel
BIIB or RGEN: Which Is the Better Value Stock Right Now?
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Q3 Earnings and Revenues Top Estimates
Repligen to Report Third Quarter 2022 Financial Results
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Company Calendar

Last Earnings
11/01/2022
Today
1/30/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,852
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$224.14
High Stock Price Forecast
$275.00
Low Stock Price Forecast
$180.00
Forecasted Upside/Downside
+24.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$128.29 million
Pretax Margin
25.08%

Debt

Sales & Book Value

Annual Sales
$670.53 million
Cash Flow
$3.76 per share
Book Value
$31.65 per share

Miscellaneous

Free Float
54,913,000
Market Cap
$10.00 billion
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • Mr. Anthony J. HuntMr. Anthony J. Hunt (Age 59)
    Pres, CEO & Director
    Comp: $2.1M
  • Mr. Jon K. SnodgresMr. Jon K. Snodgres (Age 57)
    Chief Financial Officer
    Comp: $860.08k
  • Mr. James R. BylundMr. James R. Bylund (Age 59)
    Chief Operating Officer
    Comp: $725.55k
  • Ms. Christine GebskiMs. Christine Gebski (Age 54)
    Sr. VP of Filtration & Chromatography
    Comp: $685.06k
  • Mr. Ralf KuriyelMr. Ralf Kuriyel (Age 64)
    Sr. VP of R&D
    Comp: $708.15k
  • Ms. Sondra S. Newman
    Global Head of Investor Relations
  • Ms. Kimberly Cornwell
    Global Head of Legal & Gen. Counsel
  • Mr. Stephen Tingley
    VP & Head of Global Sales
  • Ms. Rachel Goodrich
    VP of Marketing
  • Mr. Craig Harrison
    Sr. VP of Process Analytics













RGEN Stock - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price forecast for 2023?

7 Wall Street analysts have issued 12-month target prices for Repligen's shares. Their RGEN share price forecasts range from $180.00 to $275.00. On average, they predict the company's share price to reach $224.14 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2023?

Repligen's stock was trading at $169.31 on January 1st, 2023. Since then, RGEN shares have increased by 6.4% and is now trading at $180.17.
View the best growth stocks for 2023 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its earnings results on Tuesday, November, 1st. The biotechnology company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The biotechnology company had revenue of $200.74 million for the quarter, compared to analyst estimates of $192.01 million. Repligen had a trailing twelve-month return on equity of 10.98% and a net margin of 20.76%.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $3.15-$3.20 for the period, compared to the consensus earnings per share estimate of $3.20. The company issued revenue guidance of $795.00 million-$805.00 million, compared to the consensus revenue estimate of $803.99 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.98%), Pendal Group Ltd (0.84%), New York State Common Retirement Fund (0.78%), Allspring Global Investments Holdings LLC (0.54%), Sumitomo Mitsui Trust Holdings Inc. (0.24%) and Comerica Bank (0.21%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $180.17.

How much money does Repligen make?

Repligen (NASDAQ:RGEN) has a market capitalization of $10.00 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.90 on an earnings per share basis.

How many employees does Repligen have?

The company employs 1,852 workers across the globe.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.

This page (NASDAQ:RGEN) was last updated on 1/31/2023 by MarketBeat.com Staff